Older Adults With Obesity Now Match Normal-BMI Peers on Key Heart Risk Markers
A major global study finds BMI-linked gaps in blood pressure and cholesterol have nearly vanished for older adults — but young adults remain at elevated risk.
Summary
A large international study tracking adults from 1990 to 2024 found that older adults with obesity now show blood pressure and cholesterol levels similar to those with normal BMI. This convergence is largely driven by widespread use of blood pressure and cholesterol-lowering medications. However, young adults under 40 with obesity still carry significantly higher cardiovascular risk, and are rarely treated for these conditions. Experts warn this does not mean obesity is harmless — it remains linked to diabetes, kidney disease, fatty liver, cancer, and inflammation. The findings highlight a gap in preventive care for younger adults and underscore that medication use is masking, not eliminating, the broader metabolic burden of obesity.
Detailed Summary
A sweeping longitudinal study published in The Lancet reveals a striking shift in the metabolic profile of older adults with obesity, with important implications for how we understand and treat cardiovascular risk across the lifespan.
Researchers from the NCD Risk Factor Collaboration, led by Majid Ezzati of Imperial College London, analyzed data from multiple countries between 1990 and 2024. They found that mean non-HDL cholesterol and systolic blood pressure declined over time across all BMI categories. Critically, the gap between people with obesity and those with normal BMI narrowed substantially in adults over 40, to the point where, in countries like the US, England, Japan, South Korea, and Thailand, older adults with obesity were metabolically indistinguishable from — or even better off than — normal-weight peers on these two markers.
The driving force behind this convergence is medication use. Older adults with obesity are now far more likely to be prescribed antihypertensive and lipid-lowering drugs, effectively closing the risk gap that once made obesity so dangerous for cardiovascular outcomes. This reflects broader advances in preventive cardiology including earlier screening and expanding pharmacological options.
Young adults under 40 with obesity tell a different story. Their blood pressure and cholesterol gaps versus normal-weight peers have barely changed since 1990, and they are rarely treated for these conditions. Researchers suggest this may reflect how absolute cardiovascular risk — which rises with age — drives treatment decisions, leaving younger high-risk individuals undertreated.
Experts caution strongly against interpreting these findings as evidence that obesity has become benign. Obesity continues to drive diabetes, chronic kidney disease, fatty liver disease, cancer, sleep disorders, musculoskeletal problems, and systemic inflammation — none of which are captured by blood pressure or cholesterol alone. The findings instead point to a missed prevention opportunity in younger adults and a need to look beyond traditional cardiovascular biomarkers when assessing the full health burden of obesity.
Key Findings
- Older adults with obesity now have blood pressure and cholesterol similar to normal-BMI peers in several countries.
- The convergence in metabolic markers is driven largely by increased medication use in adults over 40.
- Young adults under 40 with obesity remain at significantly higher cardiovascular metabolic risk than normal-weight peers.
- Young adults with obesity are rarely treated for high blood pressure or cholesterol, representing a prevention gap.
- Obesity still drives diabetes, kidney disease, fatty liver, cancer, and inflammation regardless of these cardiovascular trends.
Methodology
This is a news report summarizing a large longitudinal multi-country observational study published in The Lancet by the NCD Risk Factor Collaboration, a highly credible global research network. The study spans 1990 to 2024 and covers multiple industrialized nations, lending substantial geographic and temporal breadth. An accompanying editorial from Yale School of Medicine adds independent expert perspective.
Study Limitations
The article does not detail which specific countries or datasets were included beyond a few named nations, limiting full assessment of generalizability. The convergence finding applies only to non-HDL cholesterol and systolic blood pressure — other critical longevity-relevant outcomes are not captured. Readers should consult the primary Lancet paper for full methodology, effect sizes, and country-level breakdowns.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: